We would like to emphasize the importance of organising a meeting to follow up on previous meetings to share information and create regional cooperation on drug trafficking. These meetings should continue to be held at regional level to share good practice and learning regional results.
From Plenary Sessions
Statement by Indonesia
Indonesia is not only a key transit country but also a destination for drug use. We have 7 million drug users. We have a crisis in amphetamine and ecstasy use. We experience challenges in security and the well being of the Indonesian population. After successes in dismantling ATS labs, we have realised that trafficking was …
Statement by Japan, Nigeria, Guatemala, Indonesia
Japan Japan has a major problem of NPS and ATS. Meth-amphetamine is a major issue for us. most was smuggled from Asian countries, however now from Europe, Mexico and Africa are increasing. Nigeria: Cannabis production is of major concern.the continued cultivation that calls for a coordinated long term international response . The increase in production of meth-amphetamine is noted with concern. we have made substantial seizures of meth-amphetamine. Guatemala: …
Statement by India
India thinks alternative developments measures are vital elements of drug control. Especially for poppy farmers for whom crop eradication will simply not work. Need to be careful to ensure alternative development program aren’t leading to corruption
Statement by SICAP
Our members states are now leading innovative projects on a range of issues including community approaches, drug driving, role of evidence and evaluation and pharmaceutical drug abuse. We are also looking at expanding therapeutic justice and drug treatment courts – many have implemented or are exploring this model Our new report will be published exploring a range of drug issues, including new regulatory models as …
Statement by HRI
Madame Chair, we wish to make three important points. First, preventing HIV among people who inject drugs is impossible without a substantial increase in funding for basic harm reduction services – in particular needle and syringe programmes and opioid substitution therapy. It has been estimated that globally less than 10% of what is needed is …